- Home
- VSTD vs IBIO Comparison
VSTD vs IBIO Comparison
Compare VSTD & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | IBIO |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 16.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | VSTD | IBIO |
|---|---|---|
| Price | $0.47 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 422.8K | ★ 1.1M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,902,861.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 30.39 | ★ 185.71 |
| 52 Week Low | $0.40 | $0.56 |
| 52 Week High | $5.63 | $6.89 |
Technical Indicators
Market Signals| Indicator | VSTD | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.61 |
| Support Level | N/A | $0.98 |
| Resistance Level | N/A | $1.30 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 70.50 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.